0001157523-20-001058.txt : 20200729 0001157523-20-001058.hdr.sgml : 20200729 20200729164955 ACCESSION NUMBER: 0001157523-20-001058 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200729 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200729 DATE AS OF CHANGE: 20200729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HOLOGIC INC CENTRAL INDEX KEY: 0000859737 STANDARD INDUSTRIAL CLASSIFICATION: X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844] IRS NUMBER: 042902449 STATE OF INCORPORATION: DE FISCAL YEAR END: 0928 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36214 FILM NUMBER: 201057683 BUSINESS ADDRESS: STREET 1: 250 CAMPUS DRIVE CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: 5082632900 MAIL ADDRESS: STREET 1: 250 CAMPUS DRIVE CITY: MARLBOROUGH STATE: MA ZIP: 01752 8-K 1 a52021954.htm HOLOGIC, INC. 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K


Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) July 29, 2020
 

HOLOGIC, INC.
(Exact Name of Registrant as Specified in Its Charter)
 

Delaware
(State or Other Jurisdiction of Incorporation)
   
001-36214
04-2902449
(Commission File Number)
(I.R.S. Employer Identification No.)

250 Campus Drive, Marlborough, Massachusetts
01752
(Address of Principal Executive Offices)
(Zip Code)
 
(508) 263-2900
(Registrant’s Telephone Number, Including Area Code)
 
(Former Name or Former Address, if Changed Since Last Report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, $.01 par value   HOLX
   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
 
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition.
 
On July 29, 2020, Hologic, Inc. issued a press release announcing its financial results for the third quarter ended June 27, 2020. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.
Limitation on Incorporation by Reference. The information furnished in this Form 8-K, including the press release attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as set forth by specific reference in such a filing.  
Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.  

Item 9.01  Financial Statements and Exhibits.
 
(d) Exhibits.
 
       
 
Exhibit
Number
 
Description
 
 
 
 
104
  
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
         
Date: July 29, 2020
 
HOLOGIC, INC.
     
 
 
By:
 
/s/ Karleen M. Oberton
graphic
 
 
 
 
Karleen M. Oberton
 
 
 
 
Chief Financial Officer
 
 EX-99.1 2 a52257438ex99_1.htm EXHIBIT 99.1
 
 Exhibit 99.1

Hologic Announces Financial Results for Third Quarter of Fiscal 2020

— Revenue of $822.9 Million Declines 3.5% due to Cynosure Divestiture, 3.1% in Constant Currency —

— Organic Revenue Increases 7.7%, 8.1% in Constant Currency, as Strong Sales of COVID Tests Offset Declines in Other Businesses —

— Company Posts GAAP Diluted EPS of $0.53, Non-GAAP Diluted EPS of $0.75 —

MARLBOROUGH, Mass.--(BUSINESS WIRE)--July 29, 2020--Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 27, 2020.

“Our strong third quarter financial results reflect the incredible contributions the Hologic team is making in the fight against the COVID-19 pandemic, and demonstrate the value of our unique set of businesses in a time of great macroeconomic uncertainty,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “I’m so proud of the incredible teamwork and work ethic that brought our two tests to market quickly, increased production capacity significantly, and installed an unprecedented number of new Panther® instruments to help our laboratory customers deliver test results when and where they are needed. Inspired by our purpose of enabling healthier lives, our team knocked down barriers by the day to deliver way beyond what we could even imagine.”

Recent Highlights

  • Revenue declined 3.5% for the quarter, or 3.1% in constant currency, due to the inclusion of revenue from the divested Cynosure business in the prior year period. Excluding material acquisitions and divestitures, organic revenue growth in the third quarter was 7.7%, or 8.1% in constant currency.
  • Molecular Diagnostics revenue of $460.3 million increased 169.3%, or 170.3% in constant currency, far exceeding internal expectations based on strong demand for the Company’s two SARS-CoV-2 assays that run on the Panther® and Panther Fusion® systems.
  • The Breast Health division launched the SuperSonic™ MACH 40 ultrasound system in the United States, expanding its suite of ultrasound technologies with its first premium, cart-based system.
  • Cash flow from operations was $223 million in the third quarter. Based on this strong cash flow, the Company repaid $250 million of debt under its revolving credit facility.

Key financial results for the fiscal third quarter are shown in the table below.

 


GAAP

 

Non-GAAP

 


Q3’20

Q3’19

Change

Increase

(Decrease)

 

Q3’20

Q3’19

Change

Increase

(Decrease)

Revenues


$822.9

$852.4

(3.5%)

 

$822.9

$852.4

(3.5%)

Gross Margin


56.6%

52.2%

440 bps

 

64.7%

61.6%

310 bps

Operating Expenses


$275.1

$299.5

(8.1%)

 

$261.1

$276.4

(5.5%)

Operating Margin


23.2%

17.0%

620 bps

 

33.0%

29.2%

380 bps

Net Margin


16.6%

11.0%

560 bps

 

23.7%

20.1%

360 bps

Diluted EPS


$0.53

$0.35

51.4%

 

$0.75

$0.63

19.0%

Throughout this press release, all dollar figures are in millions, except EPS. Some totals may not foot due to rounding. Unless otherwise noted, all results are compared to the corresponding prior year period. Non-GAAP results exclude certain cash and non-cash items as discussed under “Use of Non-GAAP Financial Measures.” Constant currency percentage changes show current period revenue results as if the foreign exchange rates were the same as those in the prior year period. Organic revenue is on a constant currency basis, and excludes the divested Blood Screening and Cynosure Medical Aesthetics businesses, as well as the acquired SSI business.

Revenue Detail

 


 


 


Increase (Decrease)

$ in millions


Q3’20


Q3’19


Global

Reported

Change


Global

Constant

Currency

Change


US

Reported

Change


International

Reported

Change


International

Constant

Currency

Change

Diagnostics


 


 


 


 


 


 


 

Cytology & Perinatal


$64.1

 

$120.3

 

(46.7%)

 

(46.3%)

 

(48.6%)

 

(43.1%)

 

(41.9%)

Molecular Diagnostics


$460.3

 

$170.9

 

169.3%

 

170.3%

 

182.4%

 

114.0%

 

118.6%

Blood Screening


$7.8

 

$14.2

 

(45.1%)

 

(45.3%)

 

(45.3%)

 

N/A

 

N/A

Total Diagnostics


$532.2

 

$305.4

 

74.3%

 

74.9%

 

90.0%

 

25.5%

 

28.1%

Excluding Blood


$524.4

 

$291.2

 

80.1%

 

80.8%

 

98.8%

 

25.5%

 

28.1%

 


 

 

 

 

 

 

 

 

 

 

 

 

 

Breast Health


 

 

 

 

 

 

 

 

 

 

 

 

 

Breast Imaging


$193.2

 

$270.0

 

(28.4%)

 

(28.1%)

 

(32.2%)

 

(14.0%)

 

(12.5%)

Interventional Breast Solutions


$30.8

 

$55.4

 

(44.4%)

 

(44.3%)

 

(46.7%)

 

(32.4%)

 

(31.0%)

Total Breast Health


$224.0

 

$325.4

 

(31.2%)

 

(30.9%)

 

(34.8%)

 

(16.5%)

 

(15.0%)

Excluding SSI


$220.1

 

$325.4

 

(32.4%)

 

(32.1%)

 

(35.0%)

 

(21.9%)

 

(20.4%)

 


 

 

 

 

 

 

 

 

 

 

 

 

 

Medical Aesthetics*


$0.0

 

$85.0

 

N/A

 

N/A

 

N/A

 

N/A

 

N/A

 


 

 

 

 

 

 

 

 

 

 

 

 

 

GYN Surgical


$51.5

 

$112.2

 

(54.1%)

 

(53.9%)

 

(54.7%)

 

(51.5%)

 

(50.1%)

 


 

 

 

 

 

 

 

 

 

 

 

 

 

Skeletal Health


$15.2

 

$24.4

 

(37.7%)

 

(37.3%)

 

(41.6%)

 

(31.5%)

 

(30.2%)

 


 

 

 

 

 

 

 

 

 

 

 

 

 

Total


$822.9

 

$852.4

 

(3.5%)

 

(3.1%)

 

2.9%

 

(22.8%)

 

(21.2%)

Excluding divested Blood and

Aesthetics businesses


$815.1

 

$753.2

 

8.2%

 

8.7%

 

11.3%

 

(2.7%)

 

(0.7%)

Excluding divestitures and SSI

acquisition (organic)


$811.2

 

$753.2

 

7.7%

 

8.1%

 

11.2%

 

(4.7%)

 

(2.8%)

* Hologic completed the divestiture of its Cynosure Medical Aesthetics business on December 30, 2019.

Other Financial Highlights

  • U.S. revenue of $660.8 million increased 2.9%. International revenue of $162.1 million decreased 22.8%, or 21.2% in constant currency. Organically, U.S. revenue of $652.6 million increased 11.2%, while international revenue of $158.6 million decreased 4.7%, or 2.8% in constant currency.
  • GAAP gross margin of 56.6% increased 440 basis points, and non-GAAP gross margin of 64.7% increased 310 basis points. The increases were due primarily to sales of SARS-CoV-2 tests and the divestiture of the lower-margin Cynosure business, partially offset by lower sales in Hologic’s other divisions as a result of the COVID-19 pandemic.
  • GAAP operating margin of 23.2% increased 620 basis points, and non-GAAP operating margin of 33.0% increased 380 basis points, primarily due to sales of SARS-CoV-2 tests and the divestiture of Cynosure.
  • The Company’s effective tax rate was 19.0% on a GAAP basis, and 22.75% on a non-GAAP basis.
  • GAAP net income attributable to Hologic of $137.9 million increased 46.9%. Non-GAAP net income attributable to Hologic of $194.7 million increased 13.5%. Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) was $299.0 million, an increase of 8.2%.
  • GAAP diluted EPS attributable to Hologic of $0.53 increased 51.4%. Non-GAAP diluted EPS attributable to Hologic of $0.75 increased 19.0%.
  • Total debt outstanding at the end of the third quarter was $3.3 billion. The Company ended the quarter with cash and equivalents of $744.2 million, and a net leverage ratio (net debt over adjusted EBITDA) of 2.4 times.
  • On a trailing 12 months basis, adjusted Return on Invested Capital (ROIC) of 12.8% increased 30 basis points compared to the prior year period.

Financial Guidance for the Fourth Quarter of Fiscal 2020

“Strong demand for our COVID tests and the ongoing recovery of our other divisions are enabling us to provide guidance for the fourth quarter of fiscal 2020,” said Karleen Oberton, Hologic’s Chief Financial Officer. “But because our business environment remains highly fluid and unpredictable, we are providing wider guidance ranges than usual.”

Hologic’s financial guidance for the fourth quarter of fiscal 2020 is shown in the table below. The guidance is based on a full year non-GAAP tax rate of approximately 22.75%, and diluted shares outstanding of approximately 265 million for the full year. Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2020 as in fiscal 2019. Current guidance assumes that recent foreign exchange rates persist for all of fiscal 2020. Organic revenue guidance is on a constant currency basis, and excludes the divested Blood Screening and Cynosure Medical Aesthetics businesses, as well as the acquired SSI business.

 


Guidance for the Fourth Quarter of Fiscal 2020

 


Guidance $


Reported %

Increase

(Decrease)


Constant

Currency %

Increase

(Decrease)


Organic %

Increase

(Decrease)

 


 


 


 


 

Q4 2020


 


 


 


 

Revenue


$925 - $1,025


6.8% to 18.4%


6.7% - 18.3%


17.4% - 30.3%

GAAP EPS


$0.73 - $0.93


386.7% - 520.0%


 


 

Non-GAAP EPS


$0.95 - $1.15


46.2% - 76.9%


 


 

Use of Non-GAAP Financial Measures

The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; and adjusted EBITDA. The Company defines its non-GAAP net income, EPS, and other non-GAAP financial measures to exclude, as applicable: (i) the amortization of intangible assets and impairment of goodwill, intangible assets and equipment; (ii) additional depreciation expense from acquired fixed assets and accelerated depreciation related to consolidation and closure of facilities; (iii) additional expenses resulting from the purchase accounting adjustment to record inventory at fair value and adjustments to contingent consideration; (iv) restructuring and divestiture charges and facility closure and consolidation charges and costs incurred to integrate acquisitions (including retention, transaction bonuses, legal and professional consulting services) and separate divested businesses from existing operations; (v) expenses related to its divested Cynosure business incurred subsequent to the disposition date primarily related to indemnification provisions for legal and tax matters (vi) transaction related expenses for divestitures and acquisitions; (vii) third-party expenses incurred related to implementing the European MDR/IVDR requirements and obtaining the appropriate approvals for its existing products (viii) debt extinguishment losses and related transaction costs; (ix) the unrealized (gains) losses on the mark-to-market of forward foreign currency contracts and foreign currency option contracts for which the Company has not elected hedge accounting; (x) litigation settlement charges (benefits) and non-income tax related charges (benefits); (xi) other-than-temporary impairment losses on investments and realized gains and losses resulting from the sale of investments; (xii) the one-time discrete impact of tax reform and other one-time impacts related to tax planning and non-operational items; (xiii) other one-time, non-recurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company's core business results; and (xiv) income taxes related to such adjustments. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income. The Company defines organic revenue to exclude the divested Blood Screening and Cynosure businesses, and the acquired SSI business.

These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The company's definition of these non-GAAP measures may differ from similarly titled measures used by others.

The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of Hologic's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic's business.

Because non-GAAP financial measures exclude the effect of items that will increase or decrease the company's reported results of operations, management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

Conference Call and Webcast

Hologic’s management will host a conference call at 4:30 p.m. ET today to discuss its financial results for the third quarter of fiscal 2020. Approximately 10 minutes before the call, dial 800-263-0877 (in the U.S. and Canada) or +1 323-794-2094 (international) and enter access code 3113758. A replay will be available approximately two hours after the call ends through Friday, August 21, 2020. The replay numbers are 888-203-1112 (U.S.) or +1 719-457-0820 (international), access code 3113758, PIN 7018. The Company will also provide a live webcast of the call at investors.hologic.com

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company’s strategies, positioning, resources, capabilities, and expectations for future performance; and the Company's outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect the Company’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the severity and duration of the COVID-19 pandemic and its impact on the U.S. healthcare system, the U.S. economy and worldwide economy; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic; continued demand for the Company’s COVID-19 TMA assay; the Company’s ability to manufacture, on a scale necessary to meet demand, its COVID-19 TMA assay as well as the Panther systems on which the assay runs; U.S., European and general worldwide economic conditions, trade relations, and related uncertainties; manufacturing risks, including the Company’s reliance on a single or limited source of supply for key components, the need to comply with especially high standards for the manufacture of many of its products and risks associated with utilizing third party manufacturers; the Company’s ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the ability of the Company to successfully manage leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the Company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including, without limitation, the Company’s ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, and the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company’s international activities and businesses; the early stage of market development for certain of the Company’s products; the Company’s leverage risks, including the Company’s obligation to meet payment obligations and financial covenants associated with its debt; cybersecurity risks; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; and competition.

The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

SOURCE: Hologic, Inc.

HOLOGIC, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In millions, except number of shares, which are reflected in thousands, and per share data)





 

 


Three Months Ended

 

Nine Months Ended

 


June 27, 2020

 

June 29, 2019

 

June 27, 2020

 

June 29, 2019

Revenues:


 


 


 


 

Product


$

701.6

 


$

704.0

 


$

2,024.5

 


$

2,054.8

 

Service and other


121.3

 


148.4

 


405.0

 


446.6

 

Total revenues


822.9

 


852.4

 


2,429.5

 


2,501.4

 

 


 


 


 


 

Cost of revenues:


 


 


 


 

Product


225.1

 


235.8

 


685.9

 


700.8

 

Amortization of acquired intangible assets


62.9

 


78.6

 


189.4

 


239.9

 

Impairment of intangible assets and equipment


—

 


—

 


25.8

 


374.6

 

Service and other


68.8

 


93.2

 


232.7

 


264.7

 

 


 


 


 


 

Gross profit


466.1

 


444.8

 


1,295.7

 


921.4

 

 


 


 


 


 

Operating expenses:


 


 


 


 

Research and development


55.1

 


61.4

 


165.5

 


171.8

 

Selling and marketing


103.5

 


143.6

 


359.0

 


423.1

 

General and administrative


105.3

 


79.9

 


260.3

 


248.5

 

Amortization of acquired intangible assets


10.2

 


11.9

 


29.5

 


40.1

 

Impairment of intangible assets and equipment


—

 


—

 


4.4

 


69.2

 

Restructuring and divestiture charges


1.0

 


2.7

 


4.8

 


6.0

 

Total operating expenses


275.1

 


299.5

 


823.5

 


958.7

 

 


 


 


 


 

Income (loss) from operations


191.0

 


145.3

 


472.2

 


(37.3

)

Interest income


0.5

 


1.2

 


4.0

 


3.3

 

Interest expense


(27.4

)


(35.1

)


(91.5

)


(106.0

)

Debt extinguishment loss


—

 


—

 


—

 


(0.8

)

Other income, net


4.3

 


2.9

 


0.1

 


5.8

 

 


 


 


 


 

Income (loss) before income taxes


168.4

 


114.3

 


384.8

 


(135.0

)

Provision (benefit) for income taxes


32.0

 


20.4

 


(232.1

)


(54.9

)

 


 


 


 


 

Net income (loss)

$

136.4

 


$

93.9

 


$

616.9

 


$

(80.1

)

 


 


 


 


 

Net loss attributable to noncontrolling interest


(1.5

)


—

 


(3.4

)


—

 

Net income (loss) attributable to Hologic


137.9

 


93.9

 


620.3

 


(80.1

)

 


 


 


 


 

Net income (loss) per common share attributable to Hologic:


 


 


 


 

Basic


$

0.53

 


$

0.35

 


$

2.35

 


$

(0.30

)

Diluted


$

0.53

 


$

0.35

 


$

2.34

 


$

(0.30

)

 


 


 


 


 

Weighted average number of shares outstanding:


 


 


 


 

Basic


259,870

 


268,932

 


263,667

 


269,586

 

Diluted


261,047

 


270,789

 


265,092

 


269,586

 













 
HOLOGIC, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In millions)





 

 


June 27, 2020


September 28, 2019

ASSETS


 


 

 


 


 

Current assets:


 


 

Cash and cash equivalents


$

744.2


$

601.8

Accounts receivable, net


728.0


648.7

Inventories


413.6


444.9

Other current assets


97.0


97.7

Total current assets


1,982.8


1,793.1

 


 


 

Property, plant and equipment, net


456.2


470.9

Goodwill and intangible assets, net


3,845.4


4,023.5

Other assets


518.7


154.6

Total assets


$

6,803.1


$

6,442.1

 


 


 

LIABILITIES AND STOCKHOLDERS' EQUITY


 


 

 


 


 

Current liabilities:


 


 

Current portion of long-term debt


$

565.5


$

271.4

Accounts payable and accrued liabilities


605.1


619.2

Deferred revenue


175.1


179.5

Total current liabilities


1,345.7


1,070.1

 


 


 

Long-term debt, net of current portion


2,731.3


2,783.6

Deferred income taxes


214.1


275.3

Other long-term liabilities


253.4


197.4

Total Hologic stockholders' equity


2,255.1


2,115.7

Noncontrolling interest


3.5


—

Total liabilities and stockholders’ equity


$

6,803.1


$

6,442.1







 
HOLOGIC, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in millions)



 

 


Nine Months Ended

 


June 27, 2020


June 29, 2019

OPERATING ACTIVITIES


 


 

Net income (loss)


$

616.9

 


$

(80.1

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:


 


 

Depreciation


62.8

 


69.7

 

Amortization of acquired intangibles


218.9

 


280.0

 

Stock-based compensation expense


53.7

 


48.5

 

Deferred income taxes


(63.3

)


(194.8

)

Asset impairment charges


30.2

 


443.8

 

Other adjustments and non-cash items


23.6

 


24.3

 

Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:


 


 

Accounts receivable


(130.5

)


(9.7

)

Inventories


(48.0

)


(81.7

)

Prepaid income taxes


(10.6

)


(11.5

)

Prepaid expenses and other assets


(290.0

)


(11.8

)

Accounts payable


(55.1

)


(30.9

)

Accrued expenses and other liabilities


40.5

 


(47.9

)

Deferred revenue


5.5

 


3.9

 

Net cash provided by operating activities


454.6

 


401.8

 

INVESTING ACTIVITIES


 


 

Acquisition of businesses, net of cash acquired


(43.2

)


(109.4

)

Net proceeds from sale of business


142.7

 


—

 

Capital expenditures


(53.2

)


(37.8

)

Increase in equipment under customer usage agreements


(44.9

)


(39.9

)

Purchase of cost-method investment


—

 


(3.0

)

Purchase of insurance contracts


(2.4

)


—

 

Purchase of intellectual property


—

 


(4.5

)

Other activity


(2.7

)


(5.3

)

Net cash used in investing activities


(3.7

)


(199.9

)

FINANCING ACTIVITIES


 


 

Proceeds from long-term debt


—

 


1,500.0

 

Repayment of long-term debt


(28.1

)


(1,462.5

)

Proceeds from revolving credit line


750.0

 


480.0

 

Repayments under revolving credit line


(250.0

)


(780.0

)

Proceeds from accounts receivable securitization agreement


16.0

 


43.0

 

Repayments under accounts receivable securitization agreement


(250.0

)


(34.0

)

Purchase of non-controlling interest


(1.8

)


—

 

Payment of deferred acquisition consideration


(24.3

)


(2.6

)

Payment of acquired long-term debt


(8.3

)


(2.5

)

Payment of debt issuance costs


—

 


(2.7

)

Purchase of interest rate caps


—

 


(1.5

)

Payment to repurchase common stock pursuant to ASR agreement


(205.0

)


—

 

Repurchase of common stock


(348.4

)


(200.1

)

Proceeds from issuance of common stock pursuant to employee stock plans


54.7

 


35.9

 

Payment of minimum tax withholdings on net share settlements of equity awards


(12.6

)


(12.4

)

Payments under finance lease obligations


(1.2

)


(1.3

)

Net cash used in financing activities


(309.0

)


(440.7

)

Effect of exchange rate changes on cash and cash equivalents


0.5

 


—

 

Net increase (decrease) in cash and cash equivalents


142.4

 


(238.8

)

Cash and cash equivalents, beginning of period


601.8

 


666.7

 

Cash and cash equivalents, end of period


$

744.2

 


$

427.9

 







 
HOLOGIC, INC.

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

(Unaudited)

(In millions, except earnings per share and margin percentages)





 

 


Three Months Ended


Nine Months Ended

 


June 27, 2020


June 29, 2019


June 27, 2020


June 29, 2019

 


 


 


 


 

Gross Profit:


 


 


 


 

GAAP gross profit


$

466.1

 


$

444.8

 


$

1,295.7

 


$

921.4

 

Adjustments:


 


 


 


 

Amortization of acquired intangible assets (1)


62.9

 


78.6

 


189.4

 


239.9

 

Impairment of intangible assets and equipment (9)


—

 


—

 


25.8

 


374.6

 

Incremental depreciation expense (2)


—

 


0.1

 


—

 


0.3

 

Integration/consolidation costs (8)


0.2

 


—

 


0.7

 


—

 

Fair value write-up of acquired inventory sold (12)


3.1

 


1.8

 


5.3

 


5.4

 

Non-GAAP gross profit


$

532.3

 


$

525.3

 


$

1,516.9

 


$

1,541.6

 

 


 


 


 


 

Gross Margin Percentage:


 


 


 


 

GAAP gross margin percentage


56.6

%


52.2

%


53.3

%


36.8

%

Impact of adjustments above


8.1

%


9.4

%


9.1

%


24.8

%

Non-GAAP gross margin percentage


64.7

%


61.6

%


62.4

%


61.6

%

 


 


 


 


 

Operating Expenses:


 


 


 


 

GAAP operating expenses


$

275.1

 


$

299.5

 


$

823.5

 


$

958.7

 

Adjustments:


 


 


 


 

Amortization of acquired intangible assets (1)


(10.2)

 


(11.9)

 


(29.5)

 


(40.1)

 

Impairment of intangible assets and equipment (9)


—

 


—

 


(4.4)

 


(69.2)

 

Incremental depreciation expense (2)


—

 


(0.3)

 


—

 


(1.0)

 

Transaction expenses (3)


(0.7)

 


(1.9)

 


(4.1)

 


(3.2)

 

Acquisition related adjustments (4)


—

 


—

 


3.8

 


—

 

Contingent consideration adjustments (6)


—

 


—

 


(0.4)

 


—

 

Litigation settlements (7)


—

 


—

 


(0.7)

 


(4.5)

 

Integration/consolidation costs (8)


(1.2)

 


(1.8)

 


(7.8)

 


(6.3)

 

Additional Cynosure related expenses (20)


(0.9)

 


—

 


(2.7)

 


—

 

Restructuring charges (8)


(1.0)

 


(2.7)

 


(4.8)

 


(6.0)

 

Purchased research and development asset charges (21)


—

 


(4.5)

 


—

 


(4.5)

 

Non-GAAP operating expenses


$

261.1

 


$

276.4

 


$

772.9

 


$

823.9

 

 


 


 


 


 

Operating Margin:


 


 


 


 

GAAP income (loss) from operations


$

191.0

 


$

145.3

 


$

472.2

 


$

(37.3)

 

Adjustments to gross profit as detailed above


66.2

 


80.5

 


221.2

 


620.2

 

Adjustments to operating expenses as detailed above


14.0

 


23.1

 


50.6

 


134.8

 

Non-GAAP income from operations


$

271.2

 


$

248.9

 


$

744.0

 


$

717.7

 

 


 


 


 


 

Operating Margin Percentage:


 


 


 


 

GAAP income (loss) from operations margin percentage


23.2

%


17.0

%


19.4

%


(1.5)

%

Impact of adjustments above


9.8

%


12.2

%


11.2

%


30.2

%

Non-GAAP operating margin percentage


33.0

%


29.2

%


30.6

%


28.7

%

 


 


 


 


 

Interest Expense:


 


 


 


 

GAAP interest expense


$

27.4

 


$

35.1

 


$

91.5

 


$

106.0

 

Adjustments:


 


 


 


 

Debt transaction costs (17)


—

 


—

 


—

 


(0.8)

 

Non-GAAP interest expense


$

27.4

 


$

35.1

 


$

91.5

 


$

105.2

 

















 

Pre-Tax Income (Loss):


 


 


 


 

GAAP pre-tax income (loss)


$

168.4

 


$

114.3

 


$

384.8

 


$

(135.0)

 

Adjustments to pre-tax earnings as detailed above


80.2

 


103.6

 


271.8

 


755.8

 

Debt extinguishment loss (5)


—

 


—

 


—

 


0.8

 

Gain from SSI (16)


—

 


—

 


(1.5)

 


—

 

Unrealized losses (gains) on forward foreign currency contracts (10)


2.0

 


2.1

 


1.2

 


0.1

 

Other (18)


—

 


—

 


0.5

 


(0.8)

 

Non-GAAP pre-tax income


$

250.6

 


$

220.0

 


$

656.8

 


$

620.9

 

 


 


 


 


 

Net Income (loss) Attributable to Hologic:


 


 


 


 

GAAP net income (loss)


$

136.4

 


$

93.9

 


$

616.9

 


$

(80.1)

 

Adjustments:


 


 


 


 

Amortization of acquired intangible assets (1)


73.1

 


90.5

 


218.9

 


280.0

 

Restructuring, integration/consolidation, Cynosure-related and transaction expenses (2) (3) (8) (20)


4.0

 


6.4

 


20.1

 


15.5

 

Incremental depreciation expense (2)


—

 


0.4

 


—

 


1.3

 

Impairment of intangible assets and equipment (9)


—

 


—

 


30.2

 


443.8

 

Purchased research and development asset charges (21)


—

 


4.5

 


—

 


4.5

 

Debt related expenses (5) (17)


—

 


—

 


—

 


1.6

 

Acquisition related adjustments (4) (6) (12)


3.1

 


1.8

 


1.9

 


5.4

 

Litigation settlements (7)


—

 


—

 


0.7

 


4.5

 

Gain from SSI (16)


—

 


—

 


(1.5)

 


—

 

Non-operating charges (10) (18)


2.0

 


2.1

 


1.8

 


(0.7)

 

Discrete impact of tax reform (11)


—

 


—

 


—

 


5.0

 

Tax effect of internal reorganization (15)


—

 


—

 


—

 


(19.2)

 

Discrete tax benefit from sale of Cynosure (19)


(1.9)

 


—

 


(312.8)

 


—

 

Income tax effect of reconciling items (13)


(23.1)

 


(28.0)

 


(68.9)

 


(177.3)

 

Non-GAAP net income


$

193.6

 


$

171.6

 


$

507.3

 


$

484.3

 

Net loss attributable to non-controlling interest


(1.1)

 


—

 


(2.2)

 


—

 

Net income attributable to Hologic


$

194.7

 


$

171.6

 


$

509.5

 


$

484.3

 

 


 


 


 


 

Net Income (loss) Percentage:


 


 


 


 

GAAP net income (loss) percentage


16.6

%


11.0

%


25.4

%


(3.2)

%

Impact of adjustments above


7.1

%


9.1

%


(4.4)

%


22.6

%

Non-GAAP net income attributable to Hologic percentage


23.7

%


20.1

%


21.0

%


19.4

%

 


 


 


 


 

Earnings Per Share Attributable to Hologic:


 


 


 


 

GAAP income (loss) per share - Diluted


$

0.53

 


$

0.35

 


$

2.34

 


$

(0.30)

 

Adjustment to net income (loss) (as detailed above)


0.22

 


0.28

 


(0.42)

 


2.08

 

Non-GAAP earnings per share – diluted (14)


$

0.75

 


$

0.63

 


$

1.92

 


$

1.78

 

 


 


 


 


 

Adjusted EBITDA:


 


 


 


 

Non-GAAP net income


$

194.7

 


$

171.6

 


$

509.5

 


$

484.3

 

Interest expense, net, not adjusted above


26.9

 


33.9

 


87.5

 


101.9

 

Provision for income taxes


57.0

 


48.4

 


149.4

 


136.6

 

Depreciation expense, not adjusted above


20.4

 


22.5

 


62.8

 


68.5

 

Adjusted EBITDA


$

299.0

 


$

276.4

 


$

809.2

 


$

791.3

 

















 
Explanatory Notes to Reconciliations:

(1)


To reflect non-cash expenses attributable to the amortization of acquired intangible assets.

(2)


To reflect non-cash fair value adjustments for additional depreciation expense related to the fair value write-up of fixed assets acquired in the Gen-Probe acquisition.

(3)


To reflect expenses with third parties related to acquisitions and divestitures typically incurred prior to when such transactions are completed. These expenses primarily comprise broker fees, legal fees, and consulting and due diligence fees.

(4)


To reflect an adjustment for the final Faxitron hold-back payment and an adjustment to reduce certain acquired accruals.

(5)


To reflect debt extinguishment losses primarily from refinancing the Company's Credit Agreement.

(6)


To reflect an adjustment to the estimated contingent consideration liability related to the Faxitron acquisition, which was payable based upon Faxitron meeting defined revenue growth metrics.

(7)


To reflect the Company's settlements of litigation. In 2019, the settlements were with Enzo and Fujifilm in the second quarter of FY19.

(8)


To reflect restructuring and divestiture charges, and certain costs associated with the Company’s integration and facility consolidation plans, which primarily include retention and transfer costs, as well as costs incurred to integrate acquisitions and dispose businesses, including consulting, legal, tax and accounting fees.

(9)


For 2020, to reflect recording the Cynosure business to fair value based upon meeting the assets-held-for-sale criteria in the first quarter of fiscal 2020 due to executing an agreement to sell the business. For 2019, to reflect an intangible asset and equipment impairment charge aggregating $443.8 million related to the Medical Aesthetics reportable segment, which was comprised solely of the Cynosure business, in the second quarter of fiscal 2019. The Company identified impairment indicators in the second quarter of fiscal 2019 and determined the undiscounted cash flows of the asset group were not sufficient to recover the carrying value of the asset group. As such, the Company determined the fair value of the asset group and recorded an impairment charge for the difference between its fair value and carrying value.

(10)


To reflect non-cash unrealized gains and losses on the mark-to market on outstanding forward foreign currency and option contracts, which do not qualify for hedge accounting.

(11)


To reflect the discrete impact of tax reform to the provision for income taxes for the nine months ended June 29, 2019. The benefit reduction of $5.0 million was primarily related to credit utilization limitations and executive compensation deduction disallowances.

(12)


To reflect the fair value step up of inventory sold during the period related to the SuperSonic Imagine and Health Beacons acquisitions in 2020 and the Focal and Faxitron acquisitions in fiscal 2019, respectively.

(13)


To reflect an estimated annual effective tax rate of 22.75% and 22.0% for fiscal 2020 and fiscal 2019, respectively.

(14)


Non-GAAP earnings per share was calculated based on 261,047 and 265,092 weighted average diluted shares outstanding for the three and nine months ended June 27, 2020, respectively and 270,789 and 271,354 for the three and nine months ended June 29, 2019, respectively.

(15)


To reflect a discrete tax benefit recorded in the nine months ended June 29, 2019 from the adjustment of the Company's current and deferred tax accounts related to an internal restructuring.

(16)


To reflect an adjustment to remeasure the Company's initial investment in SuperSonic Imagine pursuant to U.S. GAAP for purchase accounting.

(17)


To reflect the amount of debt issuance costs recorded directly to interest expense as a result of fiscal 2019 refinancing’s of the Company's Credit Agreement.

(18)


To reflect non-operating gain and charges for the sale of securities and other items not representative of the Company's core business.

(19)


To reflect a discrete tax benefit from the sale of Cynosure

(20)


To reflect additional expenses incurred related to the Cynosure disposition and indemnification provisions for legal and tax matters that existed as of the date of disposition.

(21)


To reflect the purchase of intellectual property to be used in research and development that have no future alternative use.

Reconciliation of GAAP to non-GAAP EPS Guidance:

 


Guidance Range

 


Quarter Ending

September 26, 2020

 


Low


High

GAAP Net Income Per Share


0.73

 


0.93

 

Amortization of acquired intangible assets


0.28

 


0.28

 

Restructuring, integration, and other charges


0.02

 


0.02

 

Intangible asset and equipment impairment charges


—

 


—

 

Discrete tax benefit from outside basis difference


—

 


—

 

Tax impact of exclusions


(0.08

)


(0.08

)

Non-GAAP Net Income Per Share


0.95

 


1.15

 

 


Trailing Twelve

Months ended

June 27, 2020

Return on Invested Capital:


 

 


 

Adjusted Net Operating Profit After Tax


 

Non-GAAP net income attributable to Hologic


$

684.6

 

Non-GAAP provision for income taxes


196.1

 

Non-GAAP interest expense


126.3

 

Non-GAAP other income


(6.1)

 

Adjusted net operating profit before tax


$

1,000.9

 

Non-GAAP average effective tax rate (1)


22.3

%

Adjusted net operating profit after tax


$

777.3

 

 


 

Average Net Debt plus Average Stockholders’ Equity (2)


 

Average total debt


$

3,175.2

 

Less: Average cash and cash equivalents


(586.0)

 

Average net debt


$

2,589.2

 

Average stockholders’ equity (3)


$

3,461.2

 

Average net debt plus average stockholders’ equity


$

6,050.4

 

 


 

Adjusted ROIC


 

Adjusted ROIC (adjusted net operating profit after tax above divided by average net debt plus average stockholders’ equity)


12.8

%

(1)


ROIC is presented on a TTM basis; non-GAAP effective tax rate for the three months ended September 28, 2019 was 21.05% and the nine months ended June 27, 2020 was 22.75%.

(2)


Calculated using the average of the balances as of June 27, 2020 and June 29, 2019.

(3)


Adjusted (increased) to eliminate the effect of the impairment of intangible assets of $32.2 million in fiscal 2014, the impairment of goodwill of $685.7 million and an IPR&D asset of $46.0 million in fiscal 2018, the impairment of intangible assets and equipment of $685.4 million in fiscal 2019 and the impairment of intangible assets and equipment of $30.2 million in fiscal 2020. The impact of the intangible asset impairment charges is reflected net of tax.



As of

 


June 27, 2020

Net Leverage Ratio:


 

 


 

Total principal debt


$

3,321.8

 

Total cash


(744.2

)

Net principal debt, as adjusted


$

2,577.6

 

EBITDA for the last four quarters


$

1,086.9

 

Net Leverage Ratio


2.4

 

Other Supplemental Information:

 

 

Three Months Ended

 

Nine Months Ended

 

 

June 27, 2020

 

June 29, 2019

 

June 27, 2020

 

June 29, 2019

 

 

 

 

 

 

 

 

 

Geographic Revenues

 

 

 

 

 

 

 

 

U.S.

 

80.3

%

 

75.4

%

 

76.9

%

 

75.1

%

Europe

 

12.4

%

 

11.3

%

 

13.3

%

 

12.0

%

Asia-Pacific

 

5.3

%

 

8.9

%

 

6.4

%

 

8.4

%

Rest of World

 

2.0

%

 

4.4

%

 

3.4

%

 

4.5

%

Total Revenues

 

100.0

%

 

100.0

%

 

100.0

%

 

100.0

%

 

Contacts

Michael Watts
Vice President, Investor Relations and Corporate Communications
(858) 410-8588
Michael.watts@hologic.com

EX-101.SCH 3 holx-20200729.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 holx-20200729_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Amendment Flag City Area Code Entity Address, City or Town Entity Address, Country Document Period End Date Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Local Phone Number Entity Address, Postal Zip Code Entity Address, State or Province Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Document Fiscal Year Focus Document Fiscal Period Focus Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity Emerging Growth Company EX-101.PRE 5 holx-20200729_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image0.jpg begin 644 image0.jpg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end XML 7 a52021954_htm.xml IDEA: XBRL DOCUMENT 0000859737 2020-07-29 2020-07-29 false 0000859737 8-K 2020-07-29 HOLOGIC, INC. DE 001-36214 04-2902449 250 Campus Drive Marlborough MA 01752 508 263-2900 false false false false Common Stock HOLX NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Jul. 29, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 29, 2020
Entity Registrant Name HOLOGIC, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36214
Entity Tax Identification Number 04-2902449
Entity Address, Address Line One 250 Campus Drive
Entity Address, City or Town Marlborough
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01752
City Area Code 508
Local Phone Number 263-2900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000859737
Title of 12(b) Security Common Stock
Trading Symbol HOLX
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://hologic.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports a52021954.htm a52257438ex99_1.htm holx-20200729.xsd holx-20200729_lab.xml holx-20200729_pre.xml image0.jpg http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a52021954.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a52021954.htm" ] }, "labelLink": { "local": [ "holx-20200729_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "holx-20200729_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "holx-20200729.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "holx", "nsuri": "http://hologic.com/20200729", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a52021954.htm", "contextRef": "c20200729to20200729", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://hologic.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a52021954.htm", "contextRef": "c20200729to20200729", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001157523-20-001058-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-20-001058-xbrl.zip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end